Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC)

被引:129
作者
Mukohara, T
Kudoh, S
Yamauchi, S
Kimura, T
Yoshimura, N
Kanazawa, H
Hirata, K
Wanibuchi, H
Fukushima, S
Inoue, K
Yoshikawa, J
机构
[1] Osaka City Univ, Sch Med, Dept Internal Med 1, Abeno Ku, Osaka 5458585, Japan
[2] Osaka City Univ, Sch Med, Dept Pathol, Abeno Ku, Osaka 5458585, Japan
[3] Osaka City Univ, Sch Med, Dept Surg 2, Abeno Ku, Osaka 5458585, Japan
关键词
NSCLC; EGFR; ERK; Akt; STAT3; immunohistochemistry;
D O I
10.1016/S0169-5002(03)00225-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Extracellular signal-regulated kinases (ERKs), Akt, and signal transducer and activator of transcription 3 (STAT3) are on signal transduction pathways triggered by epidermal growth factor receptor (EGFR). The purpose of this study was to evaluate the expressions of these peptides and to correlate the level of EGFR expression with downstream-activated peptide expression in non-small-cell lung cancer (NSCLC). A total of 60 specimens were studied by immunohistochemistry. EGFR overexpression was detected in 78% of specimens, but no significant relationship was found between it and any clinicopathological factors investigated. Phosphorylated (p)-ERK, p-Akt, and p-STAT3 expressions were observed in 28, 53, and 58% of specimens, respectively, and p-Akt and p-STAT3 expressions were correlated with well-differentiated tumor (P = 0.045 and 0.014, respectively). Half of the 60 specimens expressed two or three downstream-activated peptides. The level of EGFR expression was associated with expressions of p-ERK and p-Akt (P = 0.045 and 0.020, respectively). In a preliminary analysis, no peptides examined had an impact on relapse-free survival. In summary, various signal transduction pathways appeared frequently to participate in NSCLC, and the level of EGFR expression appeared to correlate with those of activated ERK and Akt, suggesting some role of receptor overexpression in more potent downstream activation. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:123 / 130
页数:8
相关论文
共 31 条
  • [1] Albanell J, 2001, CANCER RES, V61, P6500
  • [2] [Anonymous], 1981, HIST TYP LUNG TUM
  • [3] Brattström D, 1998, ANTICANCER RES, V18, P1123
  • [4] Brognard J, 2001, CANCER RES, V61, P3986
  • [5] A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers
    D'Amico, TA
    Massey, M
    Herndon, JE
    Moore, MB
    Harpole, DH
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (04) : 736 - 742
  • [6] EXPRESSION OF EPIDERMAL GROWTH-FACTOR RECEPTOR (EGF-R) IN NON-SMALL CELL LUNG-CANCER - USE OF ARCHIVAL TISSUE AND CORRELATION OF EGF-R WITH HISTOLOGY, TUMOR SIZE, NODE STATUS AND SURVIVAL
    DAZZI, H
    HASLETON, PS
    THATCHER, N
    BARNES, DM
    WILKES, S
    SWINDELL, R
    LAWSON, RAM
    [J]. BRITISH JOURNAL OF CANCER, 1989, 59 (05) : 746 - 749
  • [7] HETERODIMERIZATION AND FUNCTIONAL INTERACTION BETWEEN EGF RECEPTOR FAMILY MEMBERS - A NEW SIGNALING PARADIGM WITH IMPLICATIONS FOR BREAST-CANCER RESEARCH
    EARP, HS
    DAWSON, TL
    LI, X
    YU, H
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1995, 35 (01) : 115 - 132
  • [8] EXPRESSION AND FUNCTION OF THE INSULIN-LIKE GROWTH-FACTOR-I SYSTEM IN HUMAN NON-SMALL-CELL LUNG-CANCER AND NORMAL LUNG-CELL LINES
    FAVONI, RE
    DECUPIS, A
    RAVERA, F
    CANTONI, C
    PIRANI, P
    ARDIZZONI, A
    NOONAN, D
    BIASSONI, R
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (06) : 858 - 866
  • [9] Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO
  • [10] 2-Q